Allogene Therapeutics (ALLO) Total Liabilities (2017 - 2026)

Allogene Therapeutics has disclosed Total Liabilities across 10 years of filings, most recently posting $117.1 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $117.1 million, down 4.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $117.1 million (down 4.49% YoY), and the FY2025 annual result was $123.4 million, down 2.5% from the prior year.
• Total Liabilities came in at $117.1 million for Q1 2026 at Allogene Therapeutics, down from $123.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $158.1 million in Q1 2023 to a low of $112.8 million in Q1 2022.
• The 5-year median for Total Liabilities is $126.5 million (2024), against an average of $133.1 million.
• Across the five-year window, Total Liabilities jumped 44.92% in 2022 and dropped 20.96% in 2024, its largest moves.
• Allogene Therapeutics' Total Liabilities stood at $154.7 million in 2022, then retreated by 15.57% to $130.6 million in 2023, then declined by 3.12% to $126.5 million in 2024, then fell by 2.5% to $123.4 million in 2025, then decreased by 5.09% to $117.1 million in 2026.
• The last three Total Liabilities figures came in at $117.1 million (Q1 2026), $123.4 million (Q4 2025), and $124.4 million (Q3 2025), per Business Quant data.